Background: Memory loss is an independent predictor of mortality among heart failure patients. Twenty-three percent to 50% of heart failure patients have comorbid memory loss, but few interventions are available to treat the memory loss. The aims of this 3-arm randomized controlled trial were to (1) evaluate efficacy of computerized cognitive training intervention using BrainHQ to improve primary outcomes of memory and serum brain-derived neurotrophic factor levels and secondary outcomes of working memory, instrumental activities of daily living, and health-related quality of life among heart failure patients; (2) evaluate incremental cost-effectiveness of BrainHQ; and (3) examine depressive symptoms and genomic moderators of BrainHQ effect. Methods: A sample of 264 heart failure patients within 4 equal-sized blocks (normal/low baseline cognitive function and gender) will be randomly assigned to (1) BrainHQ, (2) active control computer-based crossword puzzles, and (3) usual care control groups. BrainHQ is an 8-week, 40-hour program individualized to each patient"s performance. Data collection will be completed at baseline and at 10 weeks and 4 and 8 months.
A mong the 6.5 million Americans with heart failure, 1 23% to 50% have comorbid cognitive dysfunction, including memory loss likely resulting from cerebral hypoperfusion and injury to the hippocampus and related structures. 2Y7 Pressler and colleagues 2 found that, among 249 heart failure patients, 23% had memory dysfunction and 19% had working memory dysfunction. Memory is a foundational cognitive process central to survival and well-being. Memory loss interferes with patients" ability to perform instrumental activities of daily living that are essential for independent living, 8 diminishes health-related quality of life, 9 and independently predicts mortality 10 and cardiovascular events. 11, 12 Despite high prevalence and severe consequences of memory loss in heart failure, there are no widely accepted evidence-based therapies to improve memory in heart failure patients. 13 Before the publication of our preliminary work, 14, 15 there were few studies in which interventions were tested to improve memory in heart failure that had potential for widespread dissemination, 16Y21 and these studies were limited by not targeting memory, 16Y21 lack of control groups, 16Y18,20 lack of inclusion of variables that may moderate intervention effect (eg, depressive symptoms, genotype), 16Y21 and small, primarily male samples. 16Y19,21 In addition, apart from our preliminary study, 15 none of these intervention studies measured depressive symptoms or serum or genomic biomarkers to evaluate intervention response and determine which patients might benefit the most from this intervention.
The purpose of this article was to present the design and rationale of the 3-arm randomized controlled trial titled ''Cognitive Intervention to Improve Memory in Heart Failure Patients'' (MEMOIR-HF). Previously, in 2 randomized controlled pilot studies (n = 40 and n = 27 heart failure patients), 14, 15, 22 preliminary evidence was found for efficacy and incremental cost-effectiveness when using the scientifically based, easily disseminated, computerized cognitive training program Brain Fitness, now part of BrainHQ. 23 In these studies, heart failure patients who completed training had improved delayed recall memory (effect size, 0.75), 14 improved working memory (effect size, 0.64), 15 and a trend of lower healthcare costs ($3821 vs $7730) 22 12 weeks after baseline. In addition, patients who completed training in the second preliminary study had increased (improved) serum brain-derived neurotrophic factor (BDNF) levels (effect size, 1.21). 15 A full-scale efficacy study will now be conducted among a larger, more diverse sample of heart failure patients without a diagnosis of dementia.
The MEMOIR-HF study has 3 specific aims and 6 hypotheses. Aim 1 is to evaluate the efficacy of BrainHQ among heart failure patients. Aim 1 hypotheses are the following:
Compared with active control and usual care control groups, heart failure patients who receive BrainHQ will have greater improvement over time (10 weeks, 4 and 8 months) in:
H.1.1. delayed recall memory (primary outcome); H.1.2. (increased) serum BDNF levels (co-primary outcome); H.1.3. working memory (secondary outcome); H.1.4. instrumental activities of daily living (secondary outcome); and H.1.5. health-related quality of life (secondary outcome).
Aim 2 is to evaluate the incremental cost-effectiveness of BrainHQ among heart failure patients. The aim 2 hypothesis is H.2.1. Using an 8-month time horizon and from societal and healthcare payer(s) perspectives, BrainHQ will be a cost-effective option in terms of dollars per quality-adjusted life years gained compared with control groups at a willingness to pay of $50 000 per quality-adjusted life years. Aim 3 is an exploratory aim to examine depressive symptoms, BDNF genotype of the Val66Met polymorphism, and apolipoprotein (APOE)-&4 allele as moderators of BrainHQ effect on primary and secondary outcomes.
Methods

Study Design
The MEMOIR-HF study (R01 NR016116; Clinical Trials.gov identifier: NCT 03035565) is a 3-arm, randomized controlled trial designed to compare computerized cognitive training using BrainHQ (commercially available from Posit Science) with computerized general cognitive stimulation with crossword puzzles (active control) and usual care with no computerized cognitive stimulation (usual care) among 264 patients with heart failure ( Figure) . The study was approved by the university institutional review board. All patients will provide written informed consent before any data collection.
Study Population
The sample will be 264 men and women with heart failure recruited from multidisciplinary heart failure and cardiology outpatient clinics at a large health system and a small health system in the Midwest. Inclusion and exclusion criteria are presented in Table 1 . The criteria were developed to ensure that enrolled patients have heart failure, are receiving guideline-derived medical therapy based on national clinical practice guidelines, can complete the computerized interventions, and do not have a diagnosis of dementia or other known major causes of memory loss. The rationale was established for the exclusion criterion Montreal Cognitive Assessment cutoff score of less than 19 based on empirical data 24 and preliminary studies. 14, 15 Trzepacz and colleagues 24 evaluated sensitivity and specificity of Montreal Cognitive Assessment test cutoff scores to detect mild cognitive impairment. The sample was 618 cases from the Alzheimer Disease Neuroimaging Initiative databases and included 219 cognitively healthy control participants, 299 participants with mild cognitive impairment, and 100 participants with Alzheimer"s disease. A Montreal Cognitive Assessment test score of less than 19 was identified by Trzepacz and colleagues 24 as appropriate to use as a screening cutoff because it would allow for inclusion of as many people as possible with mild cognitive impairment but not dementia. A Montreal Cognitive Assessment test score of less than 19 had a sensitivity of 87.3 and a specificity of 77.0 for detecting mild cognitive impairment. In addition, in preliminary studies, 14, 15 patients with a Montreal Cognitive Assessment test score less than 19 were unable to complete the computerized cognitive training intervention. Patients will be excluded from MEMOIR-HF if they are unable to complete the Montreal Cognitive Assessment test because of deficits in visual or motor skills. To ensure that patients with likely or diagnosed dementia will be excluded, medical records will be reviewed for any diagnosis of dementia, patients" physicians will verify eligibility, and if needed, data will be discussed by members of the research team including the neuropsychologist (B.G.).
Sample Size Justification and Power Analysis
Power analyses were conducted based on data from preliminary studies 14, 15, 22 to determine the required sample size to test all hypotheses. The measure of effect size was Cohen"s d. Cohen defined a small effect size as d = 0.2, a medium effect size as d = 0.5, and a large effect size as d = 0.8. 25 The MEMOIR-HF study was designed to have at least 90% power to detect effects of the size observed in the preliminary studies for memory 14 and serum BDNF 15 and 70% to 96% power for secondary outcomes. 14, 15, 22 Assuming 20% attrition, enrollment of 264 patients will result in 70 patients per 
Randomization and Stratification
Enrolled patients will be randomized within 4 patient blocks to assign patients to the 3 intervention groups (computerized cognitive training, puzzles, or usual care). 26 The 4 blocks will be constructed based on baseline cognitive function (Montreal Cognitive Assessment test score: normal, Q26, and low, 19Y25) 11, 27, 28 and gender. This method will result in 4 Patients in each block will be assigned to 1 of 3 groups with equal probability. A computer-generated randomization list will be maintained on a secure Web site and accessed by the project and data managers to determine group assignments after baseline assessment.
Evidence is lacking about which heart failure patients derive the most benefit from BrainHQ. It is unknown whether patients with different levels of baseline cognition have similar improvement with BrainHQ. The rationale for stratification by gender was based on previous heart failure studies. Although women have a similar risk for developing heart failure, women have been underrepresented in heart failure studies. In a review of 264 studies published in 2013 in 11 peerreviewed journals, the mean percentage of women in the samples was 32% across 129 studies with original data and 34% across 135 studies with data obtained from existing data sets. 30 The median percentage of women was 29% across the 264 studies. In regard to cognitive dysfunction in heart failure, men may have more cognitive dysfunction than women. In a past study among 249 heart failure patients, men had poorer memory scores than women. 2 It is unknown whether women and men have similar improvements with BrainHQ. Therefore, patients will be stratified by gender.
Computerized Cognitive Training Intervention
In MEMOIR-HF, the intervention will be the 6 BrainHQ exercises used in the preliminary studies: (1) Sound Sweeps, (2) Fine Tuning, (3) Memory Grid, (4) Syllable Stacks, (5) To-Do List Training, and (6) In the Know. Patients will be given a laptop computer and, if needed, Internet access with a mobile Internet card to perform BrainHQ. They will be taught to perform the intervention 1 hour per day, 5 days per week for 8 weeks, for a total of 40 hours.
The computerized cognitive training intervention using BrainHQ was selected for MEMOIR-HF based on scientific rationale and empirical literature. The BrainHQ is guided by knowledge of neurogenesis and neuroplasticity.
23,31Y34 Neurogenesis occurs in the hippocampus after injury, and the hippocampus may be damaged in heart failure. 31Y34 Woo and colleagues 7, 36 and Kumar and colleagues 35 documented neuronal loss and loss of axonal integrity in multiple areas of the brain of heart failure patients when compared with control participants, including the mammillary bodies, fornix, and hippocampus, which are part of the memory structures of the brain. Neurogenesis and neuroplasticity are mechanisms through which the brain may recover from events (eg, small or silent infarcts) and compensate for oxygen deprivation. 31, 32 There is promising evidence that intensive training designed to increase sensory stimulation and perform cognitively challenging activities promotes neuroplasticity and improves memory.
37Y39
BrainHQ provides core elements that are necessary for inducing neuroplasticity ( Table 2 ). The 6 core elements are (1) intensive and progressive training of the auditory system, (2) processed speech, (3) behavioral tracking, (4) working memory training, (5) attentive listening, and (6) response feedback and rewards. Intensive training (defined as 1 hour per day, 5 days per week for 8 weeks, for a total of 40 hours) provides repetitive practice that is necessary to improve precision and accuracy in understanding speech, which may improve recall. Progressive training provides exercises that are increasingly complex as the person progresses through the program. Speech used in the program is processed by an algorithm that increases the rate and complexity of speech over the training sessions to enhance the person"s ability to understand and encode speech. Behavioral tracking is used to monitor individual performance and ensure that the person is training at a threshold level that is at the uppermost level of his/her skill. This threshold training is a unique element because it tailors training to the person"s performance. Working memory training is incorporated because it is central to memory formation. For example, attentive listening is incorporated by requiring the person to press the start button to begin each exercise, which assists in focusing. Finally, feedback and rewards provided in the program may strengthen learning. 37, 39 The ability to encode, recall, and use information obtained through speech is closely linked to the ability to hear and interpret speech accurately. BrainHQ was developed to improve a person"s ability to hear speech and thereby improve the ability to encode, recall, and use information. Refining listening skills to more clearly distinguish individual sounds that are part of speech improves recall. Recall of information is quicker and more accurate. The emotional context of auditory information that is received influences a person"s ability to recall the information. Events associated with surprise and stronger emotions are more novel and easier to recall. 40 BrainHQ incorporates surprising and novel content to strengthen recall.
Previously, in the Advanced Cognitive Training for Independent and Vital Elderly Trial, Ball and colleagues 41 found that a noncomputerized cognitive training intervention improved memory, processing speed, reasoning, instrumental activities of daily living, and health-related quality of life performance among 2832 healthy older adults. 42 In addition, Wolinsky et al 43, 44 found that risk of health-related quality of life decline was reduced by 38% at 2 years (P = .004) 43 and the annual predicted healthcare expenditures declined by $223 (P = .024) at 1 year postintervention for the group trained in reasoning. 44 The Advanced Cognitive Training for Independent and Vital Elderly Trial served as the basis for a computerized cognitive training intervention tested by Mahncke and colleagues 37 among 182 healthy older adults. Adults who completed the program had significant improvements in memory compared with adults in attention control and no-contact groups. 37 In a multisite, double-blind, randomized controlled trial of this intervention among 487 older adults, Smith and colleagues 38 found that memory and working memory improvement was significantly greater in adults who received Brain Fitness (now BrainHQ) than in adults who received general cognitive stimulation. Brain Fitness was efficacious in studies among 79 older adults, 45 
47
46 and 12 47 persons with mild cognitive impairment, 32 persons with schizophrenia, 48 and 17 heart failure patients, 21 but studies were limited by small samples. The mechanism by which computerized cognitive training using BrainHQ improves memory is undetermined. One potential mechanism is that training increases serum levels of the pleiotropic neurotrophin BDNF. Brain-derived neurotrophic factor, a growth 
It is involved in the regulation of synaptic plasticity and the promotion of survival of neurons that influence learning and memory by modulating hippocampal plasticity in the adult mammalian nervous system. 49 In a randomized controlled study among 56 persons with schizophrenia, compared with 26 persons who received an active control intervention of computer games, 30 persons who completed 50 hours of computerized cognitive training using BrainHQ had significantly increased serum BDNF levels at 2 weeks (P = .03) and 10 weeks (P = .02) after training. 50 Moreover, among the 30 persons in the BrainHQ group, serum BDNF levels normalized after 10 weeks and increased serum BDNF was associated with improved quality of life (P = .01). The investigators concluded that serum BDNF may be a peripheral biomarker that is responsive to the effects of cognitive training and potentially other cognitive enhancement interventions in persons with schizophrenia. In our preliminary study, 15 compared with 9 heart failure patients who did not complete cognitive training, 11 heart failure patients who completed 40 hours of cognitive training using BrainHQ over 8 weeks had significantly increased serum BDNF levels (P = .011). Taken together, these studies support the need for further investigation and suggest that increased BDNF may contribute to or underlie the improvements observed in memory performance after computerized cognitive training using BrainHQ.
Rationale for Control Groups
Active Control Group Patients who are randomly assigned to the active control group will receive a computer-based intervention using crossword puzzles. This intervention consists of a series of crossword puzzles that are available from Internet sites that are free to users. They are visually appealing, have features for solving the puzzles, and come from multiple sources. A menu of puzzles will be provided for patients, or they may select their own. Patients will be given a laptop computer and, if needed, Internet access using a mobile Internet card to perform the puzzle intervention. They will be instructed to perform the intervention by working on the puzzles 1 hour per day, 5 days per week for 8 weeks, for a total of 40 hours to match BrainHQ time.
The rationale for this intervention is the belief that increased general cognitive activity maintains or improves cognitive function. Performing general cognitively stimulating activities may promote plasticity, but it may not be powerful enough to overcome the existing brain pathology that accompanies heart failure. There is limited evidence that completion of general interventions such as crossword puzzles generalizes to specific cognitive abilities such as memory. This intervention was designed to be consistent with the common recommendation from providers to stay cognitively active and to match time spent on BrainHQ and computer use.
Usual Care Group
Patients who are randomly assigned to the usual care group will continue to receive usual care based on national heart failure guidelines 13 but will not receive any specific computerized cognitive interventions from the research team. This group is necessary because (1) it controls for internal validity threats that may occur if only using BrainHQ and active control interventions, (2) it is hypothesized that BrainHQ is better than usual care, and (3) there are no guideline recommendations for cognitive training for heart failure. 51 Patients in this group will be offered BrainHQ after study completion at an equivalent subscription cost.
Measures
All measures have documented validity and reliability among older adults. Data will be collected by trained interviewers. Neuropsychological tests will be administered by a tester trained by research team members, including a neuropsychologist. Neuropsychological tests will be completed in isolated rooms without external distractions at the patients" homes or at the school of nursing neuropsychological testing room.
Primary Efficacy Outcome Variables
The primary efficacy outcome variables will be delayed recall memory and serum BDNF (Table 3) . Delayed recall memory will be measured using the Hopkins Verbal Learning TestYRevised Version 52,53 during faceto-face interviews conducted at the patients" homes at baseline, 10 weeks, and 4 and 8 months after baseline. Serum BDNF will be measured within 2 weeks of the face-to-face interviews at baseline, 10 weeks, and 4 and 8 months after baseline.
Secondary Efficacy Outcomes Variables
The secondary outcomes will be working memory, instrumental activities of daily living, health-related quality of life, and cost-effectiveness (Table 3) . Changes in working memory will be measured using the CogState Health One Back Accuracy Task 54,55 at baseline, 10 weeks, and 4 and 8 months after baseline. Changes in instrumental activities of daily living will be measured using the Everyday Problems Test 56 at baseline, 10 weeks, and 4 and 8 months after baseline. Changes in healthrelated quality of life will be measured using the Minnesota Living with Heart Failure Questionnaire 57 at baseline, 10 weeks, and 4 and 8 months after baseline. The costeffectiveness of the computerized cognitive training intervention will be evaluated using data on (1) time spent by research assistants training and delivering the interventions, (2) time spent by patients learning and completing interventions, (3) healthcare resource use retrieved from the electronic health record, and (4) Health Utilities Index Mark 3 58 completed at baseline, 10 weeks, and 4 and 8 months after baseline.
Potential Moderating Variables
Three potential moderating variables of the effect of computerized cognitive training using BrainHQ will be examined: depressive symptoms, BDNF gene Val66Met polymorphism, and APOE-&4. Depressive symptoms may occur in heart failure patients and influence patients" responses to cognitive training. Therefore, depressive symptoms will be evaluated as a moderating variable to deepen understanding of whether patients with high depressive symptoms have different responses to BrainHQ than patients with few or no depressive symptoms. The Patient Health Questionnaire-8 59 will be used to measure depressive symptoms.
BDNF gene Val66Met polymorphism influences hippocampal neuronal integrity, learning, and memory. The abnormality in BDNF gene termed Val66Met polymorphism was linked to learning and memory disorders in past studies 60Y62 and will be evaluated as a potential moderating variable that may influence Abbreviations: APOE, apolipoprotein; BDNF, brain-derived neurotrophic factor; BNP, brain natriuretic peptide; HF, heart failure; N/A, not applicable.
patients" response to cognitive training. Cherran and colleagues 63 reported that 35% of white persons have BDNF Val66Met polymorphism. Lang and colleagues 64 reported that 30.7% of 114 healthy adults in Germany had BDNF Val66Met polymorphism. Feher and colleagues 65 reported that 41.2% of 160 persons with Alzheimer"s disease had BDNF Val66Met polymorphism. In the preliminary MEMOIR-2 study, 15 8 of 25 heart failure patients (32%) had BDNF Val66Met polymorphism.
Apolipoprotein-&4 allele is a risk factor for late-onset Alzheimer"s disease that is associated with decreased learning and memory. 66Y69 Presence of APOE-&4 allele will be evaluated as a potential moderating variable that may influence responses to cognitive training. Farrer and colleagues 69 conducted a meta-analysis and found that the frequency of the APOE-&4 allele was 36.7% among white persons with Alzheimer"s disease, 32.2% among African American persons with Alzheimer"s disease, 13.7% among white persons without Alzheimer"s disease or other major neurological diseases, and 19.0% among African American persons without Alzheimer"s disease. Bertram and colleagues 70 found that the presence of 1 APOE-&4 allele was associated with 4.3 times greater odds of developing late-onset Alzheimer"s disease and the presence of 2 APOE-&4 alleles was associated with 15.6 times greater odds of developing late-onset Alzheimer"s disease. Corder and colleagues 71 reported an earlier onset of Alzheimer"s disease when compared with persons without APOE-&4 allele. Finally, Vogels and colleagues 72 reported that 33% of 62 heart failure patients in the Netherlands had at least 1 copy of the APOE-&4 allele. In the preliminary MEMOIR-2 study, 7 of 29 heart failure patients (24.1%) had APOE-&4 allele, 73 potentially increasing their risk for memory disorders and altering their responses to cognitive training interventions.
Sample Description Variables and Covariates
Demographics, heart failure-related clinical variables, medical comorbidities, daytime sleepiness, and balance and history of falls will be measured to provide a description of the sample and identify potential covariates (Table 3) . Measures of premorbid intellect, visual recognition memory, attention, psychomotor function, and executive function will be measured to provide a more complete description of cognitive function and assist in interpretation of outcome measures of delayed recall memory and working memory and as possible covariates.
Intervention Treatment Fidelity
Recommended best practice strategies will be implemented to ensure treatment fidelity. 74 To ensure fidelity of study design, the BrainHQ and active control interventions will be delivered for the same length of time (5 h/wk Â 8 weeks = 40 hours) and by computer platform. To ensure fidelity of provider training, intervention research assistants will be trained carefully and their performance will be monitored every 6 months over the study duration. To ensure fidelity of intervention delivery, standard-size laptop computers will be used for all intervention deliveries. Interventions delivered by computers offer advantages that strengthen intervention delivery and reduce variation in delivery. Stimuli are delivered with precision to all participants. Patient responses are measured immediately. The computer quickly adjusts exercises to match individual abilities. Training is tailored for each person daily, progress is tracked, and feedback is provided. Interventions are self-directed. Previous computer experience is not required.
To ensure fidelity of intervention receipt, intervention research assistants will explain and demonstrate interventions to patients, ask patients to give return demonstrations of accessing and performing interventions, answer questions, and provide written instructions. They will call patients weekly to monitor intervention receipt and time spent using a checklist that will be a covariate.
Mental effort used during the intervention performance will be assessed using a structured form. BrainHQ and active control group patients will be taught to complete a 4-item checklist documenting the mental effort used at the end of each intervention session. Checklists will be used to assess intervention receipt and as a covariate. 75 Time spent will be monitored using the BrainHQ program and RescueTime software for the active control puzzle group and by patient self-report time logs.
Change in clinical condition (dyspnea, fatigue, emotions, and overall health) will be monitored weekly during the 8-week intervention phase to ensure that patients" clinical condition is stable and they are able to complete the interventions. 76 When the intervention research assistants contact patients by telephone weekly, they will assess change in condition using a structured questionnaire that will be a covariate. Upon completion of the study, patients will complete a satisfaction questionnaire about the program.
Statistical Analysis
Randomization results will be compared with the preplanned randomization schedule to ensure randomization integrity. Descriptive statistics will be completed for all measures. Scores will be examined for outliers, and appropriate strategies will be used if needed. Distributions based on density plots will be examined. If data are not normally distributed, nonparametric methods will be used for analysis. Demographic, clinical, and study variables will be evaluated for baseline equivalencies before hypothesis testing. Variables (eg, age, gender, smoking status, body mass index, medications) that may influence BDNF interpretation 77 will be evaluated before hypothesis testing, although the randomized controlled trial design will likely balance these factors. The significance level will be set at P G .05 for all analyses.
The primary analyses comparing the 3 groups will be conducted using the intent-to-treat approach in which patients are considered to be in groups to which they have been randomly assigned, not on treatment or amount of treatment they actually receive. This approach is taken because it is the best method for evaluating potential effects of a treatment policy, which is our focus. Another implication of this approach is that patients who are lost to follow-up are included, ensuring that observed differences between conditions are not due to differential dropout. Use of a mixed model analysis helps achieve this goal.
Analyses for hypotheses testing efficacy of BrainHQ to improve delayed recall memory (primary outcome) and serum BDNF levels (co-primary outcome) at 10 weeks and 4 and 8 months after baseline will use the primary and co-primary dependent measures of Hopkins Verbal Learning Test-Revised delayed recall (raw score) and the serum BDNF levels. Both dependent variables are quantitative and likely to be normally distributed either in raw form or after preliminary transformations. Analysis will be conducted using a mixed model analysis 78 of repeated measures data including randomization group, time, and interactions between group and time while adjusting for the 4 patient blocks defined by baseline cognition and gender using the mixed procedure in SAS. Significant interaction between group and time will indicate differences in the changes of delayed recall and BDNF levels among the 3 groups. After significant interactions of time with treatment group, specific contrasts will be tested comparing mean outcome measures in the BrainHQ group with each of the other groups at each specific time point after baseline. Analyses for testing hypotheses for secondary outcomes are similar to analyses for testing hypotheses for primary outcomes and will involve contrasting patients who receive BrainHQ with active and usual care groups on improvements with working memory, instrumental activities of daily living, and health-related quality of life. Analyses will use mixed models as described previously.
Analyses related to aim 1 (all primary and secondary outcomes) will determine whether the effect of BrainHQ differs by level of baseline cognitive scores (Montreal Cognitive Assessment test score: normal, Q26, or low, 19Y25) or gender. Interactions between baseline cognitive function and time and between gender and time will be added to the mixed model analyses. Key tests are the product terms that will indicate whether effects of treatment differ by level of baseline cognitive function or gender. Means of outcome measures by treatment group and by time will be examined.
Some secondary analyses related to aim 1 will step outside the intent-to-treat approach by determining whether patients received the recommended dosage of the computer interventions. Time spent in training will be analyzed using continuous time data. Because HF severity, comorbidities, and change in condition may prevent some patients from adhering to interventions, New York Heart Association class, Charlson Comorbidity Index, and change in condition will be tested as potential predictors of number of hours completed and as covariates in the analyses of outcomes. With reasonable variability, the analyses will be critical in showing whether these variables predict amount of time spent completing the intervention and influence outcomes.
Aim 2 is to evaluate cost-effectiveness of the BrainHQ training intervention. All costs will be reported in a standard currency, such as 2016 United States dollars. To test the hypothesis, incremental cost-effectiveness ratios will be computed using the formula: (C 1 j C 2 ) / (E 1 j E 2 ). C 1 is the cost associated with the training intervention, C 2 is the cost associated with the control group (either active control puzzles or usual care), E 1 is the quality-adjusted life years associated with the training intervention, and E 2 is the quality-adjusted life years associated with the control group. To account for the inherent uncertainty associated with both measures of utility and costs, probabilistic cost-effectiveness acceptability curves will be calculated by bootstrapping of incremental cost-effectiveness ratios, as has become commonplace in analyses of heart failure treatments. 79 Recommendations of the Panel on Cost-Effectiveness in Health and Medicine will be followed, where possible. 80, 81 Time horizon of the analyses is 8 months (study duration), and thus, discounting is not applicable and long-term net costs will not be estimated. Univariate and multivariate sensitivity analyses will be conducted on all estimations of costs and qualityadjusted life years estimates. Mixed model analysis will be conducted on all 3 quantitative measures: estimated costs, quality-adjusted life years, and cost per quality-adjusted life years. Taking the societal perspective, the hypothesis is that the training intervention using BrainHQ will be a cost-effective option compared with the control groups. In fact, based on the pilot study, 22 a net cost savings is hypothesized. Taking the third-party perspective, the instrumental costeffectiveness ratios will be calculated using medical service costs as the measure of effectiveness.
Aim 3 is exploratory to examine depressive symptoms (measured by Patient Health Questionnaire-8), BDNF gene Val66Met polymorphism, and APOE-&4 as moderators of BrainHQ efficacy. For BDNF gene analysis, patients will be grouped as Met negative (ValVal) or Met positive (ValMet and MetMet). For APOE analysis, patients will be grouped into &4 carriers and noncarriers. The effect of BrainHQ training on all measures in aim 1 is assessed by the interactions of group with time. Analyses for aim 3 will add PHQ-8, BDNF Val66Met polymorphism, and APOE carrier status (separately) and interactions between treatment group and these variables with others in the mixed model. The key tests will be of the interactions. Power for determining these interactions may be lower than what was estimated for aims 1 and 2, but estimated treatment responses within each subgroup will provide preliminary hypothesis-generating data for future studies.
Safety Considerations
The study will follow the Policy of the National Institute of Nursing Research for Data and Safety Monitoring of Extramural Clinical Trials. Essential elements of the data and safety monitoring plan are procedures for (a) monitoring the overall study by the Investigators and Safety Monitoring Committee; (b) monitoring study safety, minimizing researchassociated risk, and protecting confidentiality of participant data; (c) identifying, reviewing, and reporting adverse events and unanticipated problems; (d) assessing new information and published data that may impact safety of participants; and (e) interim analyses.
Conclusions
To our knowledge, MEMOIR-HF will be the first adequately powered randomized trial of computerized cognitive training among heart failure patients to date. Findings will provide important new knowledge about the efficacy, cost-effectiveness, and potential moderators of a scientifically based, easily disseminated, computerized cognitive training program for memory loss in heart failure patients. Importantly, findings will help build the empirical evidence that is needed in clinical practice to address the debilitating problem of memory loss that negatively affects patients" survival and quality of life. If efficacious and costeffective, the intervention will provide a new therapeutic approach for heart failure patients and findings can be used to inform health systems to adopt it as an intervention and health insurers to provide coverage for this intervention.
